Cancer heterogeneity determined by functional proteomics

A. Szász, B. Györffy, György Marko-Varga

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Current manuscript gives a synopsis of tumor heterogeneity related to patient samples analyzed by proteomics, protein expression analysis and imaging mass spectrometry.First, we discuss the pathophysiologocal background of cancer biology as a multifactorial and challenging diseases. Disease pathology forms the basis for protein target selection. Therefore, histopathological diagnostics and grading of tumors is highlighted. Pathology is the cornerstone of state-of-the-art diagnostics of tumors today both by establishing dignity and - when needed - describing molecular properties of the cancers. Drug development by the pharmaceutical industry utilizes proteomics studies to pinpoint the most relevant targets. Molecular studies profiling affinity-interactions of the protein(s) with targeted small drug molecules to reach efficacy and optimal patient safety are today requested by the FDA and other agencies for new drug development.An understading of basic mechanisms, controlling drug action and drug binding is central, as a new era of personalized medicine becomes an important milestone solution for the healthcare sector as well as the Pharma and Biotech industry. Development of further diagnostic, prognostic and predictive tests will aid current and future treatment of cancer patients.In the paper we present current status of Proteomics that we believe requires attention in order to collectively advance forward in the fight against cancer, addressing the burning opportunities and challenges.

Original languageEnglish
JournalSeminars in Cell and Developmental Biology
DOIs
Publication statusAccepted/In press - Jul 14 2016

Fingerprint

Proteomics
Neoplasms
Pharmaceutical Preparations
Pathology
Precision Medicine
Proteins
Health Care Sector
Manuscripts
Neoplasm Grading
Drug Industry
Patient Safety
Mass Spectrometry
Industry

Keywords

  • Biomarkers
  • Cancer heterogeneity
  • Clinical study
  • Genomics
  • Multiple reaction monitoring (MRM)
  • Parallel reaction monitoring (PRM)
  • Proteomics
  • Single reaction monitoring (SRM)

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

Cancer heterogeneity determined by functional proteomics. / Szász, A.; Györffy, B.; Marko-Varga, György.

In: Seminars in Cell and Developmental Biology, 14.07.2016.

Research output: Contribution to journalArticle

@article{b6232c43d261468689762256d230a779,
title = "Cancer heterogeneity determined by functional proteomics",
abstract = "Current manuscript gives a synopsis of tumor heterogeneity related to patient samples analyzed by proteomics, protein expression analysis and imaging mass spectrometry.First, we discuss the pathophysiologocal background of cancer biology as a multifactorial and challenging diseases. Disease pathology forms the basis for protein target selection. Therefore, histopathological diagnostics and grading of tumors is highlighted. Pathology is the cornerstone of state-of-the-art diagnostics of tumors today both by establishing dignity and - when needed - describing molecular properties of the cancers. Drug development by the pharmaceutical industry utilizes proteomics studies to pinpoint the most relevant targets. Molecular studies profiling affinity-interactions of the protein(s) with targeted small drug molecules to reach efficacy and optimal patient safety are today requested by the FDA and other agencies for new drug development.An understading of basic mechanisms, controlling drug action and drug binding is central, as a new era of personalized medicine becomes an important milestone solution for the healthcare sector as well as the Pharma and Biotech industry. Development of further diagnostic, prognostic and predictive tests will aid current and future treatment of cancer patients.In the paper we present current status of Proteomics that we believe requires attention in order to collectively advance forward in the fight against cancer, addressing the burning opportunities and challenges.",
keywords = "Biomarkers, Cancer heterogeneity, Clinical study, Genomics, Multiple reaction monitoring (MRM), Parallel reaction monitoring (PRM), Proteomics, Single reaction monitoring (SRM)",
author = "A. Sz{\'a}sz and B. Gy{\"o}rffy and Gy{\"o}rgy Marko-Varga",
year = "2016",
month = "7",
day = "14",
doi = "10.1016/j.semcdb.2016.08.026",
language = "English",
journal = "Seminars in Cell and Developmental Biology",
issn = "1084-9521",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Cancer heterogeneity determined by functional proteomics

AU - Szász, A.

AU - Györffy, B.

AU - Marko-Varga, György

PY - 2016/7/14

Y1 - 2016/7/14

N2 - Current manuscript gives a synopsis of tumor heterogeneity related to patient samples analyzed by proteomics, protein expression analysis and imaging mass spectrometry.First, we discuss the pathophysiologocal background of cancer biology as a multifactorial and challenging diseases. Disease pathology forms the basis for protein target selection. Therefore, histopathological diagnostics and grading of tumors is highlighted. Pathology is the cornerstone of state-of-the-art diagnostics of tumors today both by establishing dignity and - when needed - describing molecular properties of the cancers. Drug development by the pharmaceutical industry utilizes proteomics studies to pinpoint the most relevant targets. Molecular studies profiling affinity-interactions of the protein(s) with targeted small drug molecules to reach efficacy and optimal patient safety are today requested by the FDA and other agencies for new drug development.An understading of basic mechanisms, controlling drug action and drug binding is central, as a new era of personalized medicine becomes an important milestone solution for the healthcare sector as well as the Pharma and Biotech industry. Development of further diagnostic, prognostic and predictive tests will aid current and future treatment of cancer patients.In the paper we present current status of Proteomics that we believe requires attention in order to collectively advance forward in the fight against cancer, addressing the burning opportunities and challenges.

AB - Current manuscript gives a synopsis of tumor heterogeneity related to patient samples analyzed by proteomics, protein expression analysis and imaging mass spectrometry.First, we discuss the pathophysiologocal background of cancer biology as a multifactorial and challenging diseases. Disease pathology forms the basis for protein target selection. Therefore, histopathological diagnostics and grading of tumors is highlighted. Pathology is the cornerstone of state-of-the-art diagnostics of tumors today both by establishing dignity and - when needed - describing molecular properties of the cancers. Drug development by the pharmaceutical industry utilizes proteomics studies to pinpoint the most relevant targets. Molecular studies profiling affinity-interactions of the protein(s) with targeted small drug molecules to reach efficacy and optimal patient safety are today requested by the FDA and other agencies for new drug development.An understading of basic mechanisms, controlling drug action and drug binding is central, as a new era of personalized medicine becomes an important milestone solution for the healthcare sector as well as the Pharma and Biotech industry. Development of further diagnostic, prognostic and predictive tests will aid current and future treatment of cancer patients.In the paper we present current status of Proteomics that we believe requires attention in order to collectively advance forward in the fight against cancer, addressing the burning opportunities and challenges.

KW - Biomarkers

KW - Cancer heterogeneity

KW - Clinical study

KW - Genomics

KW - Multiple reaction monitoring (MRM)

KW - Parallel reaction monitoring (PRM)

KW - Proteomics

KW - Single reaction monitoring (SRM)

UR - http://www.scopus.com/inward/record.url?scp=84995366730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995366730&partnerID=8YFLogxK

U2 - 10.1016/j.semcdb.2016.08.026

DO - 10.1016/j.semcdb.2016.08.026

M3 - Article

C2 - 27569188

AN - SCOPUS:84995366730

JO - Seminars in Cell and Developmental Biology

JF - Seminars in Cell and Developmental Biology

SN - 1084-9521

ER -